在第三级推儿童医院中药物外流:前性队列研究
Niloufar Amini1, Neda Shirvani2, Sharareh Babaei3
1Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Clinical pediatrics
|January 6, 2025
概括
儿科外流伤害与女性性别,中心线和更长的住院时间有关. 识别这些危险因素对于预防接受静脉注射治疗的儿童受到伤害至关重要.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 血管接触并发症 血管接触并发症
- 在儿科的患者安全.
背景情况:
- 在儿科医院中,外流伤害很常见,导致显著的组织损伤和长时间的住院.
- 有限的数据存在于特定的风险因素,有助于在儿科患者扩散.
- 静脉注射 (IV) 治疗是儿科护理中常见的一种程序,需要了解相关风险.
研究的目的:
- 识别和分析与接受静脉治疗的儿科患者外流伤害相关的风险因素.
- 提供数据,可以为预防策略提供信息,并改善儿科重症监护病房的患者安全.
- 调查患者人口统计学,导管注射方法和外流事件之间的关系.
主要方法:
- 一项前性队列研究,涉及500名儿科患者 (1个月至18岁) 进入儿科重症监护室 (PICU).
- 数据收集包括患者人口统计学,导管类型 (中央与外围),住院时间,药物管理和外流事件.
- 进行了统计分析,以确定潜在风险因素和外流事件之间的显著关联.
主要成果:
- 扩散的总体患病率为9.8% (500名患者中有49名).
- 确定的重大风险因素包括女性性别 (P = .002),中央静脉导管 (P = .002),长时间住院 (P < .001),意识减弱 (P = .012),以及使用磁带进行静脉固定 (P = .004).
- 参与者的平均年龄为36个月,56%是男性.
结论:
- 女性性别,中央静脉导管,延长住院时间,意识下降和静脉固定带是儿科患者扩张的重要危险因素.
- 医疗保健提供者必须主动评估这些风险因素,以尽量减少外流伤害的发生率和严重程度.
- 基于已识别的风险因素实施有针对性的预防措施对于改善接受静脉治疗的脆弱儿科患者群体的治疗结果至关重要.
相关概念视频
Factors Affecting Drug Response: Overview
1.6K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.6K
Pharmacovigilance
730
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
730


